These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22277499)

  • 1. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
    Nagai Y; Nukina N
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
    Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
    Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.
    Popiel HA; Nagai Y; Fujikake N; Toda T
    Mol Ther; 2007 Feb; 15(2):303-9. PubMed ID: 17235308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.
    Popiel HA; Burke JR; Strittmatter WJ; Oishi S; Fujii N; Takeuchi T; Toda T; Wada K; Nagai Y
    J Amino Acids; 2011; 2011():265084. PubMed ID: 22312459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.
    Popiel HA; Nagai Y; Fujikake N; Toda T
    Neurosci Lett; 2009 Jan; 449(2):87-92. PubMed ID: 18603372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.
    Takeuchi T; Nagai Y
    Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29019918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.
    Popiel HA; Takeuchi T; Fujita H; Yamamoto K; Ito C; Yamane H; Muramatsu S; Toda T; Wada K; Nagai Y
    PLoS One; 2012; 7(11):e51069. PubMed ID: 23226463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein.
    Bauer PO; Goswami A; Wong HK; Okuno M; Kurosawa M; Yamada M; Miyazaki H; Matsumoto G; Kino Y; Nagai Y; Nukina N
    Nat Biotechnol; 2010 Mar; 28(3):256-63. PubMed ID: 20190739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y; Fujikake N; Popiel HA; Wada K
    Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain-Targeting Delivery of Two Peptidylic Inhibitors for Their Combination Therapy in Transgenic Polyglutamine Disease Mice via Intranasal Administration.
    Yang M; Zhang Q; Wang Q; Sørensen KK; Boesen JT; Ma SY; Jensen KJ; Kwan KM; Ngo JCK; Chan HYE; Zuo Z
    Mol Pharm; 2018 Dec; 15(12):5781-5792. PubMed ID: 30392378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila.
    Zhang Q; Tsoi H; Peng S; Li PP; Lau KF; Rudnicki DD; Ngo JC; Chan HY
    Dis Model Mech; 2016 Mar; 9(3):321-34. PubMed ID: 26839389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
    Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
    Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A toxic monomeric conformer of the polyglutamine protein.
    Nagai Y; Inui T; Popiel HA; Fujikake N; Hasegawa K; Urade Y; Goto Y; Naiki H; Toda T
    Nat Struct Mol Biol; 2007 Apr; 14(4):332-40. PubMed ID: 17369839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathomechanism of polyglutamine diseases and strategic design for their therapies].
    Nukina N
    Rinsho Shinkeigaku; 2008 Nov; 48(11):913-4. PubMed ID: 19198116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
    Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.